Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism

Table 2 Clinical trials for direct oral anticoagulants reported recurrent venous thromboembolism and reported mayor bleed outcomes compared to cancer subgroup

Study	Intervention DOAC	Control	Reported efficacy (rVTE) (%)	Cancer subgroup efficacy (%)	Reported safety (MB) (%)	Cancer subgroup safety (%)	Yr
AMPLIFY[17]	Apixaban	Enoxaparin + Warfarin	2.30	3.70	0.6	2.3	2013
AMPLIFY-EXT[18]	Apixaban	Placebo	4.00	NA	0.2	NA	2013
RE-COVER[19]	Dabigatran	Heparin + Warfarin	3.10	3.10	1.60	4.20	2009
RE-COVER II[20]	Dabigatran	Heparin + Warfarin	2.30	2.40	1.20	< 1	2013
RE-MEDY[21]	Dabigatran	Warfarin	1.80	3.30	0.90	NA	2013
RE-SONATE[21]	Dabigatran	Placebo	0.40	NA	0.30	NA	2013
HOKUSAI-VTE[22]	Edoxaban	Warfarin	3.20	3.70	1.40	4.50	2013
EINSTEIN-Choice[25]	Rivaroxaban	Aspirin	1.50	NA	0.5	NA	2017
EINSTEIN-DVT[23]	Rivaroxaban	Enoxaparin+ Warfarin	2.10	3.40	0.8	14.4	2010
EINSTEIN-EXT[26]	Rivaroxaban	Placebo	1.30	2.10	0.7	12.3	2016
EINSTEIN-PE[24]	Rivaroxaban	Enoxaparin+ Warfarin	2.10	2	1.1	12.3	2012

DOAC: Direct oral anticoagulant; LMWH: Low molecular weight heparin; VKA: Vitamin K antagonist; rVTE: Recurrent venous thromboembolism; MB: Major bleeding.